Calidi Put On Notice By NYSE For Non-Compliance In Stockholders' Equity; Shares Fall By 5%

Calidi Biotherapeutics, Inc. (CLDI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Calidi Biotherapeutics Reports Third Quarter 2026 Financial Results and Recent Business Highlights - Continued to advance the development of CLD-401 towards the clinic - Presented new CLD-401 data and in situ TCE platform advances at the ESMO Congress 2026 - Received

Calidi Biotherapeutics, Inc. (CLDI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Calidi Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights - Received positive pre-IND feedback from the U.S. FDA for CLD-401, indicating agreement on the current development strategy toward a first-in-human study targeting fi

Calidi Biotherapeutics (NYSE American: CLDI) reported a positive US FDA pre-IND outcome for CLD-401, agreeing on pharmacology, toxicology, CMC and phase I protocol strategy. The company targets first patient dosing in Q1 2027 and expects first data in Q2 2027. It also cited new RedTail in situ TCE data, added a board member, and cut G&A by about $1M from Q1 2025 to Q1 2026.

AstraZeneca (AZN) received FDA approval for its IMFINZI plus enfortumab vedotin-ejfv regimen for certain bladder cancer patients. The treatment showed a 49% reduction in event-free survival risk and a 42% reduction in death risk in the VOLGA trial. This marks the third bladder cancer indication for IMFINZI in two years, according to AstraZeneca.

The U.S. Supreme Court will hear Robinhood's appeal in a lawsuit over its 2021 IPO, alleging undisclosed weakening trading activity. Robinhood reported a 48% drop in crypto trading volume in October, while equity trading rose 2%. The company had 28.9 million funded customers, up 1.8 million year-over-year. Robinhood's IPO was priced at $38 per share, raising $2.1 billion. The company denies wrongdoing, stating its IPO documents warned of potential declines in trading activity.

US Commerce Secretary Howard Lutnick will testify before the Senate Banking Committee regarding export controls on Nvidia's semiconductor chips and the Megaspeed investigation. Senator Tim Scott requested the testimony, citing national security concerns. Nvidia CEO Jensen Huang was also asked to testify. The Commerce Department is investigating alleged diversions of Nvidia chips to China via Megaspeed, a Singapore-based company with suspected Chinese intelligence ties.